Establishing biomarkers for soft tissue sarcomas
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989100%3A27740%2F24%3A10255832" target="_blank" >RIV/61989100:27740/24:10255832 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.tandfonline.com/doi/full/10.1080/14737140.2024.2346187" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/14737140.2024.2346187</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14737140.2024.2346187" target="_blank" >10.1080/14737140.2024.2346187</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Establishing biomarkers for soft tissue sarcomas
Popis výsledku v původním jazyce
IntroductionSoft tissue sarcomas (STS) are a rare and diverse group of tumors. Curative options are limited to localized disease, with surgery being the mainstay. Advanced stages are associated with a poor prognosis. Currently, the prognosis of the patient is based on histological classification and clinical characteristics, with only a few biomarkers having entered clinical practice.Areas coveredThis article covers extensive recent research that has established novel potential biomarkers based on genomics, proteomics, and clinical characteristics. Validating and incorporating these biomarkers into clinical practice can improve prognosis, prediction of recurrence, and treatment response. Relevant literature was collected from PubMed, Scopus, and clinicaltrials.gov databases (November 2023).Expert opinionCurrently, defining prognostic markers in soft tissue sarcomas remains challenging. More studies are required, especially to personalize treatment through advanced genetic profiling and analysis using individual tumor and patient characteristics.
Název v anglickém jazyce
Establishing biomarkers for soft tissue sarcomas
Popis výsledku anglicky
IntroductionSoft tissue sarcomas (STS) are a rare and diverse group of tumors. Curative options are limited to localized disease, with surgery being the mainstay. Advanced stages are associated with a poor prognosis. Currently, the prognosis of the patient is based on histological classification and clinical characteristics, with only a few biomarkers having entered clinical practice.Areas coveredThis article covers extensive recent research that has established novel potential biomarkers based on genomics, proteomics, and clinical characteristics. Validating and incorporating these biomarkers into clinical practice can improve prognosis, prediction of recurrence, and treatment response. Relevant literature was collected from PubMed, Scopus, and clinicaltrials.gov databases (November 2023).Expert opinionCurrently, defining prognostic markers in soft tissue sarcomas remains challenging. More studies are required, especially to personalize treatment through advanced genetic profiling and analysis using individual tumor and patient characteristics.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
—
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Expert Review of Anticancer Therapy
ISSN
1473-7140
e-ISSN
1744-8328
Svazek periodika
24
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
15
Strana od-do
407-421
Kód UT WoS článku
001209884100001
EID výsledku v databázi Scopus
2-s2.0-85192051439